Arbutus Biopharma Taken Off Of Chardan's Sell List By: Benzinga via Benzinga June 16, 2016 at 09:29 AM EDT Chardan has upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) to Neutral following its underperformance versus Arrowhead Pharmaceuticals ... Read More >> Related Stocks: Alnylam Pharmaceuticals Arbutus Biopharma Corp Assembly Biosciences Benitec Biopharma Ltd ADR Gilead Sciences Johnson & Johnson S&P Biotech SPDR